Bio Pharma Dive
NOVEMBER 9, 2021
Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday. The biotech is researching how to make medicines from transfer RNA molecules.
World of DTC Marketing
NOVEMBER 9, 2021
SUMMARY: Quantitative and qualitative data was gained through surveys with EPG Health’s multi-stakeholder databases (HCP, pharma, and service providers) and interviews conducted with pharma execs by Impatient Health. The objective was to identify new and preferred pathways for the creation and delivery of medical information. Key Findings 1 : HCPS ARE IN CONTROL AND PHARMA KNOWS IT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
NOVEMBER 7, 2021
This cross-sectional study of individuals from the French CONSTANCES cohort assesses whether the belief in having been infected with SARS-CoV-2, having serological test–confirmed COVID-19 infection, or both are associated with persistent physical symptoms often attributed to long COVID in the general adult population.
Pharma Times
NOVEMBER 11, 2021
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
Bio Pharma Dive
NOVEMBER 8, 2021
Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras.
pharmaphorum
NOVEMBER 12, 2021
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The MOATAI-VIR algorithm, developed by scientists at Emory University and Georgia Tech, was put through its paces in a study that showed it was able to predict 24 out of 26 clinical manifestations of COVID-19, including acute respiratory distress, blood clotting issues, cytokine storms, brain fog, and loss of sm
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
NOVEMBER 9, 2021
Dutch stem cell company Neuroplast has announced positive Phase 1 results for its Neuro-Cells investigational stem cell treatment in patients suffering from Traumatic Spinal Cord Injury (TSCI).
Bio Pharma Dive
NOVEMBER 12, 2021
The industry giant and mainstay of corporate America will separate its consumer health business from its drug and medical device units, which will retain the J&J brand.
Pharma Times
NOVEMBER 12, 2021
Researchers have said that next generation vaccines for COVID-19 should aim to induce a response against ‘replication proteins’
BioSpace
NOVEMBER 7, 2021
Researchers aren’t sure why the mRNA vaccines appear to, in rare cases, cause heart inflammation. The FDA said the risk appears higher within seven days of the second jab of the vaccines.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
NOVEMBER 9, 2021
Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the first country in the world to approve the routine use of the therapy in this setting. The Scottish Medicines Consortium (SMC) has approved Tagrisso (osimertinib) for use within NHS Scotland as a monotherapy for adjuvant treatment after tumour removal in adult patients with stage IB-IIIA NSCLC whose tumours have epidermal growth factor (EGF
Bio Pharma Dive
NOVEMBER 12, 2021
Detailed results presented Thursday show no difference between the biotech's drug and placebo on the study's main measures. But a seeming benefit in a subgroup of patients convinced the company to plan another trial.
Scienmag
NOVEMBER 12, 2021
Carbon is the building block of all known life on our planet. The carbon cycle regulates the release and absorption of carbon from a number of natural sources — including the ocean, soil, geochemical processes, and human emissions — to maintain a delicate balance of this crucial element in our world. Credit: Kristin Rose Jutras […].
BioSpace
NOVEMBER 8, 2021
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 8, 2021
The UK government has announced £248 million in spending over the next year for a project to make it easier for patient test results and scans to be shared between hospitals, labs and GP surgeries. The aim is to “digitise diagnostics care” across the NHS, reducing the time it takes to diagnose health problems and get treatment started earlier, helping to address the massive backlog in care caused by the pandemic, according to a Department of Health and Social Care (DHSC) statement.
Bio Pharma Dive
NOVEMBER 11, 2021
Data presented at an Alzheimer's meeting raised more questions about the seeming benefit of Roche and AC Immune's drug semorinemab, which they claim is the first of its kind to slow deterioration of memory.
Pharma Times
NOVEMBER 8, 2021
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
BioSpace
NOVEMBER 10, 2021
?Scientists are conducting research into the possibility of creating a vaccine that activates T cells that targets not just SARS-CoV-2 but also its variations, even the ones that cause common colds.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
XTalks
NOVEMBER 11, 2021
While chicken is the most common type of poultry consumed around the world, to some, its meaning has changed considerably over the last few years thanks to the growing vegan movement. Today, on World Chicken Day, let’s explore how chicken has evolved throughout the last decade and determine whether vegan chicken can legally be called “chicken.”. Plant-based meat alternatives have helped reshape the landscape of the food industry over the last few years.
Bio Pharma Dive
NOVEMBER 11, 2021
The biotech claimed its NIH partners were involved only after a key discovery was made "by Moderna scientists using Moderna technology." The dispute could end up in court.
Scienmag
NOVEMBER 10, 2021
Last spring, as Laura Stieghorst watched Elon Musk’s SpaceX rocket blast off from Cape Canaveral, the University of Miami undergraduate wished the billionaire would pour as much money into saving the planet from climate change as he was enabling people to leave it. Credit: Jenny Hudak/University of Miami Last spring, as Laura Stieghorst watched Elon […].
BioSpace
NOVEMBER 8, 2021
AstraZeneca announced its plans to create a new, separate division for vaccines and antibody therapies, specifically its COVID-19 vaccine developed with the University of Oxford and other COVID-19 antibody treatments.
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for ARISTADA+INITIO+KIT Aristada Initio Kit is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Alkermes Inc drug ARISTADA INITIO KIT appeared first on DrugPatentWatch - Make Better Decisions.
Bio Pharma Dive
NOVEMBER 8, 2021
Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.
Scienmag
NOVEMBER 10, 2021
In the Namib desert—one of the driest places in the world—a tiny species of beetle climbs the dunes, leans its body toward the wind, and catches the only source of water it can: passing droplets of fog. Credit: Credit: Aida Shahrokhian In the Namib desert—one of the driest places in the world—a tiny species of […].
BioSpace
NOVEMBER 7, 2021
While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
NOVEMBER 8, 2021
After co-developing one of the world’s most widely used COVID-19 vaccines, Pfizer announced positive trial results on Friday for its investigational antiviral pill, revealing that the pill could cut the risk of hospitalization and death by 89 percent. The drug, called Paxlovid (a combination of PF-07321332 and ritonavir), is among the first orally administered antivirals against SARS-CoV-2, as other authorized or approved antivirals, such as remdesivir, are administered through intravenous (IV)
Bio Pharma Dive
NOVEMBER 9, 2021
The new agreement raises the financial upside of molnupiravir, which Merck believes could be a $7 billion product in 2022. But Pfizer's rival drug, which has produced seemingly superior efficacy, could affect those projections.
Intouch Solutions
NOVEMBER 8, 2021
“Craft matters, and it is the next frontier in our industry,” says Intouch chief creative officer Susan Perlbachs. “We have a responsibility to elevate our work and to make it un-ignorable, so that vital messages can do their job.”. Fortunately, craft is something we’re brimming with at Intouch, and our latest campaign — which symbolizes our unique approach to solving client challenges in creative ways others can’t imagine — dials it up to eleven.
BioPharma Reporter
NOVEMBER 10, 2021
A new specialized lab, office and collaboration space for over 100 life science and health technology professionals, entrepreneurs, and researchers was recently announced for The Campus, Cherrywood in South Dublin, Ireland.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
359 
Let's personalize your content